Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant

Lancet. 2023 Nov 4;402(10413):1623-1625. doi: 10.1016/S0140-6736(23)01634-3. Epub 2023 Oct 18.
No abstract available

Publication types

  • Letter

MeSH terms

  • Heterocyclic Compounds, 2-Ring*
  • Humans
  • Neoplasms* / drug therapy
  • Receptors, Neurokinin-3
  • Thiadiazoles*

Substances

  • fezolinetant
  • Receptors, Neurokinin-3
  • Heterocyclic Compounds, 2-Ring
  • Thiadiazoles